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Introduction {#sec1}
============

Our current understanding of what governs tuberculosis (TB) disease progression and control in humans is limited by the lack of existing knowledge about how protective immune responses are generated within TB lesions. The central dogma suggests that within TB lesions, infected macrophages are activated by antigen-specific CD4^+^ T cells that secrete interferon-gamma (IFN-γ), restricting the growth and dissemination of *Mycobacterium tuberculosis* (*Mtb*) ([@bib42]). This dogma has since been revised to recognize the importance of additional T cell subsets that elicit protective immune responses to *Mtb*. There is increasing evidence that CD8^+^ T cells are important for effective control of *Mtb* because they kill infected host cells directly and facilitate long-lived immunological memory ([@bib9], [@bib18], [@bib53], [@bib58]). Humans fail to generate robust CD8^+^ T cell memory during *Mtb* infection, even after successful treatment ([@bib59]); similar findings have been observed in animal models ([@bib7], [@bib15]). Poor memory T cell responses also remain a caveat of most existing TB vaccine candidates to date ([@bib16], [@bib44]) and were thought to have contributed to the failure of the highly anticipated MVA85A vaccine trial ([@bib55]). Failure to develop and sustain this essential antigen-experienced CD8^+^ T cell population during *Mtb* infection suggests that there may be a defect in key regulatory mechanisms that foster the differentiation of CD8^+^ effector T cells into long-lived, multi-potent memory cells.

T cell dysfunction plays a key role in the loss of immune control and aberrant inflammation associated with some chronic viral infections and cancers. There is evidence from chronic viral infections such as lymphocytic choriomeningitis virus (LCMV) and hepatitis B virus (HBV) that persistent antigen exposure compromises CD8^+^ T cell function, driving the cell into a state of exhaustion marked by an altered global transcriptional program, metabolic insufficiencies, increased expression of inhibitory markers (PD-1, CTLA-4, LAG-3, and 2B3), and poor effector function ([@bib3], [@bib4], [@bib49], [@bib65]). This phenomenon is also observed in the nutrient-deficient tumor microenvironment, where tumor-infiltrating CD8^+^ T lymphocytes (TILs) fail to elicit productive anti-tumor responses ([@bib10]). The availability of nutrients (or lack thereof) within densely packed TB lesions could have similar detrimental effects on T cell responses during chronic *Mtb* infection. Increased expression of inhibitory markers, as well as the terminal differentiation marker CD57 (KLRG-1), have been detected on antigen-specific T cells from human TB patients ([@bib34], [@bib50], [@bib61]). This work, in conjunction with functional studies in mice ([@bib25]), suggests that CD8^+^ T cell immunity is suboptimal during chronic *Mtb* infection because of T cell exhaustion.

Distinct metabolic programs are initiated upon T cell activation, differentiation, and effector and memory transitions in the lymphocyte life cycle ([@bib5]). This metabolic reprogramming can be altered by chemical signals from the surrounding environment or immune checkpoint regulators (e.g., PD-1, CTLA-4) on the cell surface, limiting effector T cell differentiation and function ([@bib45]). For instance, functional impairments in CD8^+^ T cells in the tumor microenvironment have been linked to upstream metabolic dysregulation ([@bib23], [@bib52]). Because many parallels exist between the tumor microenvironment and TB lesions, similar mechanisms could be responsible for the breakdown in T cell-mediated immunity observed during chronic *Mtb* infection.

Increased TB risk is associated with several immunometabolic disease states, including type 2 diabetes and malnutrition ([@bib13], [@bib26], [@bib35]), suggesting that an important component of TB etiology involves immunometabolic derangement. Despite decades of extensive immunological characterization of the immune response during *Mtb* infection, little is known about how metabolic reprogramming contributes to the development of dysfunctional immune responses in TB. Recent work from our lab has revealed that *Mtb* rewires macrophage energy metabolism to support its survival in the host by decelerating flux through glycolysis and the tricarboxylic acid (TCA) cycle and limiting ATP availability ([@bib11]). Further characterization of these events *in vivo* is required to understand how metabolic reprogramming of specific immune cell populations (i.e., macrophages, neutrophils, T cells, etc.) contributes to *Mtb* persistence within TB lesions.

In this study, we hypothesize that *Mtb* maintains persistence during chronic infection by inducing environmental cues that lead to the metabolic and functional deterioration of CD8^+^ T cell responses. To test this hypothesis, we used a combination of flow cytometry, bioenergetic, metabolomic, and transcriptomic analyses to compare CD8^+^ T cell populations purified from mice infected with virulent *Mtb*, or the non-pathogenic vaccine strain, *Mycobacterium bovis* Bacillus Calmette-Guérin (BCG). Comparing the effects of these two distinct mycobacterial infections on CD8^+^ T cell immunometabolism over time allows us to identify signatures that correspond with *Mtb* pathogenesis. In doing so, we have identified important interactions between metabolism and the breakdown of *Mtb* immunity that lay the groundwork for future mechanistic studies in this interdisciplinary field.

Results {#sec2}
=======

To test our hypothesis that chronic *Mtb* infection coincides with metabolic alterations in the CD8^+^ T cell population that impede downstream effector function and hinder disease resolution, we compared mice infected with pathogenic *Mtb* with mice infected with the non-pathogenic vaccine strain, *M. bovis* BCG. We compared the metabolic and functional responses of total and *Mtb*-specific CD8^+^ T cells from *Mtb*-infected mice with those from uninfected (UI) and BCG-infected mice at early (day 21 \[D21\], D35) and late (week 12 \[W12\]) time points post-infection ([Figure 1](#fig1){ref-type="fig"}A). Using this experimental approach, we investigated how the metabolic and immunologic characteristics of CD8^+^ T cells coincided with two kinetically distinct bacterial infections in the lung over time ([Figure 1](#fig1){ref-type="fig"}B).Figure 1Divergence in CD8^+^ T Cell Transcriptional Signatures Early and Late in *Mtb* Infection Compared with BCG(A) Experimental timeline.(B) Colony-forming units (CFUs) in the lung over the course of infection.(C) The number of genes differentially expressed by CD8^+^ T cells purified from the lungs of infected mice at D21 and W12 relative to uninfected (UI) mice.(D) Principal-component analysis (PCA) of gene expression patterns from individual mice at D21 and W12.(E) *Z* scores of differentially expressed genes (fold change ≥ ±2, p \< 0.05) grouped according to canonical pathways identified by Ingenuity Pathway Analysis (QIAGEN). Red, activated; blue, repressed; white, not significantly altered. Only selected pathways are shown.(F) Select differentially expressed genes grouped according to functional category.Heatmap shading is based on fold-change gene expression values relative to UI mice at the designated time point. Genes considered significant have fold-change values ≥ ±2. Genes not assigned fold-change values (undetected) are shown in white. CFU data are representative of three independent experiments (n = 5 mice per group). Error bars are mean ± SD.

CD8^+^ T Cell Transcriptional Signatures Diverge between *Mtb* and BCG Infections {#sec2.1}
---------------------------------------------------------------------------------

To examine the molecular signatures present in CD8^+^ T cells over the course of infection with pathogenic or non-pathogenic mycobacteria, we purified total CD8^+^ T cells from the lungs of mice infected with *Mtb* or BCG at D21 (early) and W12 (late) post-infection and compared them with cells from UI mice. Transcriptional profiling revealed 2,990 and 1,766 genes were differentially regulated in CD8^+^ T cells from *Mtb*-infected mice compared with BCG at D21 and W12, respectively. Compared with UI mice, 429 differentially expressed genes were common to both infections at D21, while at W12, this number had decreased to 341 ([Figure 1](#fig1){ref-type="fig"}C). The magnitude of genes differentially expressed during *Mtb* infection relative to BCG when normalized to UI (1,747 versus 703 at D21 and 1,567 versus 821 at W12 for *Mtb* and BCG, respectively; [Figure 1](#fig1){ref-type="fig"}C), as well as the influence of time (D21 versus W12), suggests that different infection kinetics early on could play a role in promoting protective versus pathogenic T cell responses over time. Principal-coordinate analysis ([Figure 1](#fig1){ref-type="fig"}D) revealed greater similarities in global gene expression patterns between UI and BCG-infected mice compared with *Mtb*, suggesting that *Mtb* infection more substantially alters T cell function. A heatmap and hierarchical clustering of these differentially expressed genes (relative to UI) further illustrates that the gene expression patterns are more similar at D21 and W12 in BCG infection than *Mtb* at the same time points ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Next, we used Ingenuity Pathway Analysis (IPA) to identify canonical pathways significantly activated/repressed (*Z* score; [Figure 1](#fig1){ref-type="fig"}E) or enriched (p value; [Figure S1](#mmc1){ref-type="supplementary-material"}B) in these CD8^+^ T cell populations. Most pathways affected by infection---especially those pertaining to T cell activation, effector functions, apoptosis, and metabolism---became activated during *Mtb* infection compared with their UI counterparts, particularly at W12; in contrast, these pathways were not activated in T cells from BCG-infected mice at D21, only at W12, further emphasizing the differences in T cell activation programs induced by these two infections ([Figure 1](#fig1){ref-type="fig"}E). Pathways linked to immunometabolism were of particular interest, including type 1 and type 2 diabetes mellitus signaling, PPARα/RXRα activation, cyclic AMP (cAMP)-mediated signaling, and HIF1α signaling. Analysis of selected differentially expressed genes revealed significant upregulation of genes pertaining to effector function, such as granzymes, perforins, and lymphotoxins, and genes relating to homing and T cell migration, as well as striking increases in genes associated with inhibitory receptor expression and apoptosis; these trends were most prominent in T cells from *Mtb*-infected mice at W12 ([Figure 1](#fig1){ref-type="fig"}F). Several genes involved in metabolism were also differentially expressed, suggesting that CD8^+^ T cells from *Mtb* and BCG infections have distinct metabolic and functional signatures ([Figure 1](#fig1){ref-type="fig"}F). Interestingly, most of the metabolic genes we detected decreased in expression relative to UI and BCG-infected mice, except for *Smpd3* and *Acsbg1*, genes involved in lipid metabolism.

These data highlight differences in the molecular signatures identified in lung CD8^+^ T cell populations over time in *Mtb*- and BCG-infected mice. CD8^+^ T cells from *Mtb* infection are highly activated at D21; expression of genes associated with this inflammatory transcriptomic signature continues to increase at W12, coinciding with the upregulation of genes associated with T cell exhaustion ([@bib65]), suggesting that prolonged activation and inflammatory signaling may impair T cell function over time. In contrast, BCG infection induces a transcriptomic signature that appears to repress inflammation early on, suggesting that the CD8^+^ T cell response may be more fine-tuned to control inflammation and resolve infection. These data provide fresh insight into how metabolism and effector functions are closely linked and identify key nodes of regulation that could be targeted to prevent the immunopathology associated with chronic TB disease.

Inhibitory Receptor Expression Is Increased upon *Mtb* Infection, Corresponding with Decreased Glucose Uptake {#sec2.2}
-------------------------------------------------------------------------------------------------------------

Transcriptional profiling of CD8^+^ T cells from *Mtb*-infected mice revealed that by W12, inhibitory receptor expression (*Pdcd1*, *Ctla4*, *Lag3*) was significantly upregulated relative to cells from UI and BCG-infected mice. Upregulation of these receptors could be indicative of functional exhaustion or restrained T cell activation, a mechanism intended to limit lethal immune-mediated pathology ([@bib48]). We observed an increase in the proportion of PD-1^+^ CD8^+^ T cells in *Mtb*-infected mice at early and late time points post-infection compared with BCG ([Figure 2](#fig2){ref-type="fig"}A). An even higher percentage of CD8^+^ T cells were CTLA-4^+^ ([Figure 2](#fig2){ref-type="fig"}B). These markers were further increased on *Mtb*-specific T cells, identified using the major histocompatibility complex (MHC) I-restricted TB10.4~4−11~ tetramer (TB10.4-TET^+^ cells). Co-expression of multiple inhibitory receptors on the cell surface has been suggested to be an early indicator of declining effector function ([@bib64]). Although most CTLA-4^+^ cells did not co-express PD-1, CTLA-4^+^PD-1^+^ co-expression was increased on TB10.4-TET^+^ cells by W12 ([Figure 2](#fig2){ref-type="fig"}C).Figure 2Elevated Inhibitory Receptor Expression Corresponds with Decreased Glucose Uptake in CD8^+^ T Cells(A and B) Proportion of total or *Mtb*-specific (TB10.4-TET^+^) CD8^+^ T cells expressing (A) PD-1 or (B) CTLA-4 over the course of *Mtb* or BCG infection.(C) Proportion of cells co-expressing PD-1 and CTLA-4 at 12 weeks post-infection.(D) Proportion of KLRG-1-expressing cells during infection.(E and F) Glucose uptake measured by incorporation of the glucose analog 2-NBDG in total or TB10.4-TET^+^ CD8^+^ T cells (E) along with representative histograms (F).(G and H) 2-NBDG uptake in CD8^+^ T cells expressing (or not expressing) PD-1 (G) with representative histogram (H) at 12 weeks post-infection.All data represent CD8^+^ T cells purified from the lungs of uninfected (UI), *Mtb*-infected, or BCG-infected mice; TB10.4-TET^+^ cells are from *Mtb*-infected mice. 2-NBDG, 2-\[*N*-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino\]-2-deoxyglucose. Statistics, unless otherwise indicated, are relative to UI. Data are representative of three independent experiments (n = 5 mice per group). "p ≤ 0.05, ^\#^p ≤ 0.01 ^∞^p ≤ 0.005, and ^∗^p ≤ 0.001 by one-way ANOVA or unpaired Student's t test. Error bars are mean ± SD.

Transcriptomic analyses also indicated upregulation of *Klrg1* in CD8^+^ T cells from *Mtb*-infected mice at W12 post-infection. We observed a steady increase in the proportion of KLRG-1^+^ cells over time in total and *Mtb*-specific CD8^+^ T cells from *Mtb*-infected mice, and by W12, KLRG-1 was expressed on nearly 80% of TB10.4-TET^+^ cells ([Figure 2](#fig2){ref-type="fig"}D).

Next, we tested whether the transcriptional changes we observed in metabolic genes could be linked to differences in glucose uptake. Glucose uptake was diminished in CD8^+^ T cells from *Mtb*-infected mice at D21, D35, and W12 post-infection ([Figures 2](#fig2){ref-type="fig"}E and 2F). This effect was enhanced in TB10.4-TET^+^ cells. On the basis of recent evidence that PD-1 alters metabolic reprogramming in T cells and hinders the transition from oxidative phosphorylation (OXPHOS) to glycolysis during effector differentiation ([@bib45]), we looked at expression of PD-1 in the context of glucose uptake. To test whether there was a reciprocal relationship between glucose uptake and PD-1 expression, we gated on PD-1^+^ and PD-1^−^ populations in activated CD44^+^CD8^+^ T cells (gating strategy, [Figure S2](#mmc1){ref-type="supplementary-material"}). Glucose uptake was reduced in PD-1^+^ cells compared to PD-1^−^ cells, except in TB10.4-TET^+^ cells, in which glucose uptake remained low regardless of PD-1 expression ([Figures 2](#fig2){ref-type="fig"}G and 2H). Although the reciprocal relationship between glucose uptake and PD-1 expression was observed in CD8^+^ T cells from all groups (UI, *Mtb*, BCG), the higher proportion of PD-1^+^ cells present during *Mtb* infection suggests that these shifts in metabolism could have greater implications in TB disease. Although we were unable to compare glucose uptake with cytokine production, because of assay incompatibility, we determined that PD-1 expression had little effect on IFN-γ or TNF-α production ([Figure S3](#mmc1){ref-type="supplementary-material"}).

These results confirm findings initially observed in our global gene expression analysis ([Figure 1](#fig1){ref-type="fig"}E) and highlight how increased inhibitory receptor expression may affect metabolic reprogramming during *Mtb* infection. The increased proportion of cells expressing PD-1, CTLA-4, and KLRG-1 in total and TB10.4-TET^+^ populations in conjunction with decreased glucose uptake suggests that these receptors may participate in metabolic control events that impair the T cell response as chronic *Mtb* infection progresses.

Mitochondrial Respiration Deteriorates in CD8^+^ T Cells during *Mtb* Infection, Increasing Their Dependency on Glycolysis {#sec2.3}
--------------------------------------------------------------------------------------------------------------------------

To test whether metabolic reprogramming occurs in CD8^+^ T cells during *Mtb* infection compared with BCG, we used extracellular metabolic flux analysis to measure mitochondrial respiration and extracellular acidification ([Figure 3](#fig3){ref-type="fig"}A) following stress induced by mitochondrial inhibition in a cell mito stress test (CMST; see [STAR Methods](#sec5){ref-type="sec"}; [Figure 3](#fig3){ref-type="fig"}B). On D21, CD8^+^ T cells from BCG and *Mtb*-infected mice had comparable rates of basal respiration, as indicated by similar oxygen consumption rates (OCRs) and extracellular acidification rates (ECARs) ([Figure 3](#fig3){ref-type="fig"}C), CMST profiles ([Figure 3](#fig3){ref-type="fig"}D), and maximal respiratory capacity (MRC)/spare respiratory capacity (SRC) values ([Figure 3](#fig3){ref-type="fig"}E). Relative to UI mice, infection reduced basal respiration as well as the cells' ability to cope under mitochondrial stress. A bioenergetic phenogram (OCR as a function of ECAR) can be used to illustrate the energy phenotype of a cell. Using this approach, cells can be described as aerobic, energetic, glycolytic, or quiescent. At D21, CD8^+^ T cells from *Mtb*- and BCG-infected mice displayed an intermediate energy phenotype that was less aerobic and less glycolytic than UI cells ([Figure 3](#fig3){ref-type="fig"}F). By D35, basal OCR had decreased in cells from *Mtb*-infected mice, and basal ECAR had increased in both *Mtb* and BCG groups compared with D21 ([Figure 3](#fig3){ref-type="fig"}G), although UI cells still maintained higher basal levels of both parameters. The CMST at D35 revealed that T cells from BCG-infected mice performed better under mitochondrial stress than cells from *Mtb*-infected mice ([Figure 3](#fig3){ref-type="fig"}H), evidenced by higher MRC/SRC values ([Figure 3](#fig3){ref-type="fig"}I); they also displayed a more energetic/glycolytic energy phenotype than cells from *Mtb* infection ([Figure 3](#fig3){ref-type="fig"}J). By W12, basal OCR and ECAR were further reduced in cells from *Mtb*-infected mice compared with earlier time points, while basal respiration in the UI and BCG groups stayed consistent with D35 measurements ([Figure 3](#fig3){ref-type="fig"}K). By W12, we were able to purify enough TB10.4-TET^+^ cells to run an additional CMST and compare *Mtb*-specific T cells with total CD8^+^ cells. Interestingly, TB10.4-TET^+^ cells at W12 displayed even lower rates of basal respiration (OCR) and ECAR than total CD8^+^ T cells from *Mtb*-infected mice ([Figure 3](#fig3){ref-type="fig"}K). When the CMST profiles ([Figure 3](#fig3){ref-type="fig"}L) and all associated parameters ([Figure 3](#fig3){ref-type="fig"}M) were compared at W12, distinct differences were observed between *Mtb* and BCG infections. Mitochondrial respiration had deteriorated in CD8^+^ T cells from mice chronically infected with *Mtb*; these cells had a diminished ability to cope under stress, evidenced by decreased MRC/SRC values ([Figure 3](#fig3){ref-type="fig"}M); all other parameters tested were also significantly reduced. Furthermore, all of these effects appeared more pronounced in the *Mtb*-specific TB10.4-TET^+^ population. By W12, total CD8^+^ and TB10.4-TET^+^ T cells from *Mtb*-infected mice displayed "quiescent" energy phenotypes, compared with UI (energetic) and BCG (intermediate) cell populations ([Figure 3](#fig3){ref-type="fig"}N). Notably, a similar bioenergetic shift toward this quiescent energy phenotype was observed in *Mtb*-infected macrophages ([@bib11]). To correlate these bioenergetic shifts with changes in the relative abundance of naive, effector, and memory T cell subsets found in the CD8^+^ T cell populations from UI, BCG-infected, and *Mtb*-infected mice, we measured surface expression of CD44 and CD62 and found that the distribution of naive, effector, and memory cells in BCG-infected mice more closely resembled UI mice ([Figure S4](#mmc1){ref-type="supplementary-material"}).Figure 3*Mtb* Infection Suppresses Mitochondrial Respiration and Increases Glycolytic Dependency(A and B) Aerobic respiration within the mitochondria in the mammalian cell (A) and the cell mito stress test (CMST) profile generated during extracellular flux (XF) analysis (B). XF analysis was performed on purified lung CD8^+^ T cells during *Mtb* or BCG infection.(C) Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) at baseline.(D--N) OCR measured during a CMST (D) with associated bioenergetic parameters (E) and corresponding phenogram after uncoupling with FCCP at D21 post-infection (F), D35 post-infection (G--J), and W12 post-infection (K--N).(O) CMST profile with/without anti-CD3/anti-CD28 activator beads.(P and Q) OCR and ECAR at baseline with/without activation (P) and phenogram before/after activation at baseline (Q), performed at D35 post-infection.(R) Glycolysis, measured by the change in ECAR pre- and post-injection with glucose.TB10.4-TET^+^ cells are from *Mtb*-infected mice. A&R, antimycin A and rotenone; F, carbonyl cyanide-4-\[trifluoromethoxy\] phenylhydrazone or FCCP; O, oligomycin;. Statistics, unless otherwise indicated, are relative to uninfected (UI). Data are representative of three independent experiments (n = 5 mice per group). "p ≤ 0.05, ^\#^p ≤ 0.01, ^∞^p ≤ 0.005, and ^∗^p ≤ 0.001 by one-way ANOVA. Error bars are mean ± SD.

Next we examined the capacity of CD8^+^ T cells from infected mice to shift their bioenergetic metabolism in response to activation *ex vivo*. CMST profiles generated in the presence or absence of anti-CD3/anti-CD28 activator beads revealed distinct bioenergetic activation capacities among CD8^+^ T cells from UI, *Mtb*-infected, or BCG-infected mice ([Figure 3](#fig3){ref-type="fig"}O). CD8^+^ T cells from BCG-infected mice were most efficient at ramping up glycolysis (ECAR) and OXPHOS (OCR) upon activation ([Figures 3](#fig3){ref-type="fig"}P and 3Q). Although T cells from *Mtb*-infected mice were able to increase ECAR to the same extent as UI cells, their ability to ramp up mitochondrial OXPHOS was impaired ([Figures 3](#fig3){ref-type="fig"}P and 3Q).

To investigate whether glycolytic capacity was altered in CD8^+^ T cells during *Mtb* infection, cells were subjected to a glycolysis stress test (GST). ECAR was measured before and after the addition of glucose (ΔECAR), which indicates how dependent cells are on glucose (and glycolysis) for energy. Under conditions of glucose deprivation, we observed that CD8^+^ T cells from *Mtb*-infected mice were more dependent on glycolysis than cells from UI or BCG groups at all time points measured, and was highest at D35 ([Figure 3](#fig3){ref-type="fig"}R). Intriguingly, these data are distinct from the glucose uptake (2-NBDG) studies ([Figures 2](#fig2){ref-type="fig"}E and 2F); these two datasets convey different aspects of glucose uptake and glycolytic dependency. The GST involves a glucose deprivation step, demonstrating the cells' reliance on glucose as a fuel source, while the 2-NBDG study, performed without glucose restriction, provides a better understanding of the cells' ability to take up glucose under basal conditions. Low basal rates of ECAR and OCR ([Figures 3](#fig3){ref-type="fig"}C, 3G, and 3K) observed during the CMST corroborate the 2-NBDG studies, suggesting that glucose uptake is low because cell metabolism (OXPHOS and glycolysis) is low. Similar observations were described in T cells from mice chronically infected with LCMV ([@bib3]).

T cells can switch their dependency from glucose to fatty acids (FAs) depending on their differentiation state ([@bib57]). After mitochondrial uncoupling with carbonyl cyanide-4-\[trifluoromethoxy\] phenylhydrazone (FCCP), we blocked FA oxidation (FAO) using the Cpt1a inhibitor, etomoxir. We did not observe any differences in FAO dependency in any group (UI, *Mtb*, BCG), indicating that the differences in OCR we observed in earlier experiments were not due to altered FA metabolism ([Figure S5](#mmc1){ref-type="supplementary-material"}).

In sum, these data highlight the presence of distinct bioenergetic signatures in CD8^+^ T cells from pathogenic and non-pathogenic infections over time. We show that mitochondrial respiration deteriorates in total and *Mtb*-specific CD8^+^ T cells as *Mtb* infection progresses, promoting a state of metabolic quiescence; this compromised mitochondrial function is also observed upon activation, when cells from *Mtb* infection fail to ramp up OXPHOS to the same extent as cells from UI or BCG groups. To compensate for the decline in OXPHOS, CD8^+^ T cells from *Mtb*-infected mice shift their dependency toward glycolysis. Unlike *Mtb*, CD8^+^ T cells from BCG-infected mice regain their respiratory capacity over time. These data provide insights into the possible virulence mechanisms of *Mtb* and demonstrate how metabolic reprogramming could contribute favorably or detrimentally to disease outcome.

*Mtb* Infection Induces Glycolytic Reprogramming in CD8^+^ T Cells {#sec2.4}
------------------------------------------------------------------

To further investigate the increased dependency on glycolysis observed in CD8^+^ T cells during *Mtb* infection ([Figure 3](#fig3){ref-type="fig"}R), we used stable isotope labeling (D-glucose-^13^C~6~) to measure the level of ^13^C incorporation into metabolites involved in glycolysis and the TCA cycle. At both D21 and D35, pyruvate and lactate metabolite pools were significantly more enriched with M+3 isotopologues in T cells from *Mtb*-infected mice compared with UI and BCG metabolite pools ([Figure S6](#mmc1){ref-type="supplementary-material"}A). At W12, only pyruvate was significantly increased in T cells from *Mtb*-infected mice. These results corresponded with elevated ATP and ADP levels at D21 and D35 compared with BCG, although there were fewer differences in the levels of these species compared with UI cells, suggesting that ATP molecules may be generated in similar amounts but through different metabolic pathways in these cells ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Because there was no corresponding increase in OCR linked to ATP production in CD8^+^ T cells during *Mtb* infection ([Figures 3](#fig3){ref-type="fig"}E, 3I, and 3M), these data suggest that the increase in ATP observed is due to residual substrate-level phosphorylation. To determine whether ATP is produced by glycolysis rather than the TCA cycle during *Mtb* infection, we examined the total levels of ^13^C incorporation in the TCA cycle intermediates citrate and succinate. Total incorporation (%M+) into citrate at D21, D35, and W12 increased in CD8^+^ T cells during *Mtb* infection relative to cells from UI and BCG-infected mice; however, no differences were observed in succinate ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Increased levels of citrate, but not succinate, suggest that citrate is being shunted back into the cytosol to fuel macromolecular synthesis via acetyl-CoA, a hallmark of T cell activation ([@bib8]). Using this carbon tracing approach, we confirm that *Mtb* infection triggers glycolytic reprogramming in CD8^+^ T cells, particularly at D35, verifying our bioenergetic analyses ([Figure 3](#fig3){ref-type="fig"}R).

Dysfunctional Mitochondria Accumulate in CD8^+^ T Cells during Chronic *Mtb* Infection {#sec2.5}
--------------------------------------------------------------------------------------

Persistent antigen stimulation during chronic infection perpetuates inflammatory signals that can affect the metabolic health, function, and lifespan of a cell. An early indicator of T cell exhaustion is the accumulation of dysfunctional mitochondria, characterized by decreased mitochondrial membrane potential (ΔΨ~m~), increased mitochondrial mass (MM), and increased mitochondrial reactive oxygen species (mROS) ([@bib3], [@bib49]). To investigate whether the decline in OXPHOS observed in CD8^+^ T cells during *Mtb* infection could be due to an accumulation of dysfunctional mitochondria, we quantified MM and ΔΨ~m~ in CD44^+^ effector T cells. At D21 post-infection, MM increased in *Mtb*-specific TB10.4-TET^+^ cells and in total CD44^+^ CD8^+^ T cells from BCG-infected mice; this effect was abrogated by D35 in BCG but was sustained in TB10.4-TET^+^ cells ([Figure 4](#fig4){ref-type="fig"}A). MM was significantly higher in total and TB10.4-TET^+^ cells from *Mtb*-infected mice at W12; this corresponded with a decrease in ΔΨ~m~ that was most pronounced at W12 ([Figure 4](#fig4){ref-type="fig"}B). Next, we gated on MTG^+^MTDR^low^ cells, identifying T cells with depolarized mitochondria ([Figure 4](#fig4){ref-type="fig"}C); the proportion of cells with depolarized mitochondria increased over the course of infection in total and TB10.4-TET^+^ cells from *Mtb*-infected mice as well as in T cells from BCG, although to a lesser extent ([Figure 4](#fig4){ref-type="fig"}C). By W12, close to 40% of TB10.4-TET^+^ cells had depolarized mitochondria.Figure 4*Mtb* Infection Promotes Accumulation of Dysfunctional Mitochondria and Mitochondrial ROS in TB10.4-TET^+^ CellsMitochondrial profiling of total and *Mtb*-specific CD44^+^CD8^+^ T cells in *Mtb*- and BCG-infected mice.(A and B) Mitochondrial mass, measured by MitoTracker Green (MTG) mean fluorescence intensity (MFI) (A), and mitochondrial membrane potential, measured by MitoTracker Deep Red (MTDR) MFI (B), with representative histograms at W12.(C) Proportion of CD44^+^CD8^+^ T cells with depolarized mitochondria identified as MTG^high^MTDR^low^ (triangle gate), with representative plots at W12.(D) Proportion of CD44^+^CD8^+^ T cells that are MitoSOX^+^ (MtSox).(E) MFI of mROS in CD44^+^CD8^+^ T cells and representative histogram at W12.(F--H) MTG (F), MTDR (G), and mROS (H) in *Mtb*-specific TB10.4-TET^+^ cells expressing CTLA-4 and/or PD-1 with representative histograms at D35 post-infection.TB10.4-TET^+^ cells are from *Mtb*-infected mice. Statistics, unless otherwise indicated, are relative to uninfected (UI). Data are representative of three independent experiments (N = 5 mice per group). "p ≤ 0.05, ^\#^p ≤ 0.01, ^∞^p ≤ 0.005, and ^∗^p ≤ 0.001 by one-way ANOVA. Error bars are mean ± SD.

Mitochondrial ROS has been associated with a loss of ΔΨ~m~ ([@bib66]). *Mtb* infection increased the proportion of MitoSOX^+^ cells and the signal intensity (mean fluorescence intensity \[MFI\], corresponding with increased mROS production) over time, particularly in TB10.4-TET^+^ cells ([Figures 4](#fig4){ref-type="fig"}D and 4E). Although it is known that mROS is induced upon T cell activation, high and sustained levels of mROS have been shown to be detrimental to mitochondrial function ([@bib17]).

Next, we investigated whether inhibitory receptor expression corresponded with the accumulation of dysfunctional mitochondria. CD8^+^ T cells from *Mtb*-infected mice that had the highest MM, lowest ΔΨ~m~ and elevated mROS expressed CTLA-4, alone or in conjunction with PD-1 ([Figures 4](#fig4){ref-type="fig"}F--4H). Interestingly, cells expressing PD-1 alone had fewer dysfunctional mitochondria and resembled cells not expressing either inhibitory receptor (CTLA-4^--^ PD-1^--^).

Together, these results suggest that chronic *Mtb* infection coincides with an accumulation of effector CD8^+^ T cells that display increased MM, decreased ΔΨ~m~ and high mROS, all features of dysfunctional mitochondria. This population is particularly enriched in TB10.4-TET^+^ cells, as well as on cells expressing CTLA-4, suggesting that this receptor may be linked to downstream regulation of mitochondrial metabolism or mitophagy.

Cytokine Production by *Mtb*-Specific CD8^+^ T Cells Can Be Modulated by Glycolytic Intervention {#sec2.6}
------------------------------------------------------------------------------------------------

Metabolic reprogramming is often reflected by changes in downstream effector function ([@bib8], [@bib43]). To identify whether changes in bioenergetics and mitochondrial health reflect downstream effector function, we investigated the impact of *Mtb* infection on cytokine production in CD8^+^ T cells. IFN-γ production increased in total and TB10.4-TET^+^ CD44^+^CD8^+^ effector T cells from *Mtb*-infected mice compared with CD44^+^CD8^+^ T cells from UI and BCG-infected mice at D21 and D35 post-infection ([Figure 5](#fig5){ref-type="fig"}A). By W12, the proportion of IFN-γ-producing cells decreased, matching those detected in cells from UI and BCG groups. TNF-α production increased at D35 in total and TB10.4-TET^+^ T cells from *Mtb*-infected mice and this trend was maintained at W12 ([Figure 5](#fig5){ref-type="fig"}B). Interestingly, IL-2 production decreased over time in *Mtb*-infected mice compared with the UI and BCG groups ([Figure 5](#fig5){ref-type="fig"}C).Figure 5Metabolic Intervention Modulates Cytokine Production in TB10.4-TET^+^ Cells(A--C) IFNγ (A), TNFα (Β), and IL-2 (C) production in CD44^+^CD8^+^ T cells purified from the lungs of uninfected (UI), *Mtb*-infected, or BCG-infected mice after re-stimulation with PMA/ionomycin.(D) The proportion of polyfunctional T cells within each CD44^+^CD8^+^ T cell subset, on the basis of co-expression of IFNγ, TNFα, and/or IL-2 (single, double, or triple combinations).(E and F) Fold change in IFNγ production following treatment with 2-DG (E) or etomoxir (F) relative to untreated cells re-stimulated with PMA/ionomycin.(G) Cytokine production by TB10.4-TET^+^ cells in the presence/absence of 2-DG or etomoxir.(H) Glucose uptake (2-NBDG MFI) in cells treated with or without PMA/ionomycin with or without 2-DG or etomoxir and representative histogram. Measurements shown in (G) and (H) represent D35 post-infection.TB10.4-TET^+^ cells are from *Mtb*-infected mice. 2-DG, 2-deoxyglucose. Statistics, unless otherwise indicated, are relative to UI. Data are representative of three independent experiments (N = 5 mice per group). "p ≤ 0.05, ^\#^p ≤ 0.01, ^∞^p ≤ 0.005, and ^∗^p ≤ 0.001 by one-way ANOVA. Error bars are mean ± SD.

Polyfunctionality is an important characteristic of robust T cell responses that can be lost when effector function declines ([@bib61]). The number of polyfunctional CD44^+^CD8^+^ T cells we observed was extremely small in all groups. The percentage of total CD44^+^CD8^+^ T cells expressing more than one cytokine was highest in BCG-infected mice at D21 post-infection, while total and TB10.4-TET^+^ cells from *Mtb*-infected mice demonstrated the highest degree of polyfunctionality at D35 ([Figure 5](#fig5){ref-type="fig"}D). Polyfunctionality decreased in all groups at W12; the only notable difference was an increase in the proportion of single cytokine-producing TB10.4-TET^+^ cells that predominantly produced TNF-α ([Figure 5](#fig5){ref-type="fig"}B).

Next, we investigated the metabolic flexibility of CD8^+^ effector T cells by examining how specific metabolic inhibitors modulated their cytokine production. Inhibiting glycolysis with 2-deoxyglucose (2-DG) revealed that total and TB10.4-TET^+^ cells from *Mtb*-infected mice were more reliant on glycolysis for IFN-γ production than cells from UI or BCG groups ([Figure 5](#fig5){ref-type="fig"}E). Similarly, shifting metabolism from OXPHOS to glycolysis using etomoxir enhanced IFN-γ production in total and TB10.4-TET^+^ cells from *Mtb*-infected mice to a greater extent than cells from UI or BCG groups ([Figure 5](#fig5){ref-type="fig"}F). The lack of cytokine production observed in UI and BCG-infected mice in the presence of etomoxir suggests that these cells may be hardwired to resist glycolytic reprogramming in their current state.

To further investigate the effects of glycolytic reprogramming on polyfunctionality and glucose uptake in TB10.4-TET^+^ cells, we used metabolic inhibitors in combination with 2-NBDG. Inhibiting glycolysis with 2-DG reduced the frequency of TB10.4-TET^+^ cells co-expressing IFN-γ and TNF-α, while the same cells treated with etomoxir resulted in an increase in the IFN-γ^+^TNF-α^+^ subset ([Figure 5](#fig5){ref-type="fig"}G). Correspondingly, glucose uptake decreased in TB10.4-TET^+^ cells exposed to 2-DG, and increased after treatment with etomoxir, except at W12, where 2-NBDG levels appear unaffected by metabolic intervention ([Figure 5](#fig5){ref-type="fig"}H).

Here, we identify differences in the timing, quantity, and quality of the cytokine response in CD8^+^ effector T cells during infection. We show that cytokine production peaks at D35 in TB10.4-TET^+^ cells, and that this response is dominated by IFN-γ and TNF-α. By W12, IFN-γ production wanes, along with the frequency of polyfunctional cells, and TNF-α producers remain. IL-2 production also decreases over time. Measuring cytokine production in the presence of 2-DG or etomoxir reveals that CD8^+^ T cells from *Mtb*-infected mice rely more on glycolysis than BCG or UI cells to produce IFN-γ; moreover, cytokine production can be increased or decreased by shifting cell metabolism toward or away from glycolysis. The ability to modulate cytokine responses in this way illustrates how targeted metabolic intervention could be used to beneficially enhance or restrain T cell responses during *Mtb* infection.

Metabolic Reprogramming by Metformin Alters Effector Function and Rejuvenates Mitochondrial Respiration in CD8^+^ T Cells during *Mtb* Infection {#sec2.7}
------------------------------------------------------------------------------------------------------------------------------------------------

Metformin (MET) is an existing US Food and Drug Administration (FDA)-approved drug that has been proposed to have therapeutic potential for the effective treatment of TB ([@bib40], [@bib51], [@bib67]). When MET is used in combination with anti-*Mtb*-targeting drugs, it can act synergistically to further reduce bacillary burden in mice infected with *Mtb* ([@bib51]). There are multiple mechanistic targets of MET, including AMPK signaling and GAPDH, but most of these mechanisms point to aspects of mitochondrial biology ([@bib6], [@bib21], [@bib41], [@bib63]). We hypothesized that MET could improve the outcome of TB disease by targeting immunometabolic checkpoints required to control infection. To test this hypothesis, we infected mice with *Mtb*, initiated MET treatment on day 7 post-infection and analyzed the bioenergetic and functional readouts of lung CD8^+^ T cells at D21 and D35 post-infection ([Figure 6](#fig6){ref-type="fig"}A).Figure 6Metformin Rejuvenates OXPHOS and Reduces Inflammatory Cytokine Production in TB10.4-TET^+^ Cells(A) Experimental timeline.(B and C) CFUs in the lungs of mice treated with or without metformin (MET) over the course of infection (B) and corresponding pathology scores performed by morphometric analysis (Visiopharm) on lung tissue sections stained with H&E (C). Total CD8^+^ T cells purified from the lungs of uninfected (UI) or *Mtb*-infected mice treated with or without MET were analyzed using XF or flow cytometry.(D) OCR at baseline.(E--K) OCR measured during a cell mito stress test (CMST) (E) with associated bioenergetic parameters (F) and corresponding phenogram (G) after uncoupling with FCCP at D21 post-infection and (H--K) D35 post-infection.(L) Glycolysis, measured by the change in ECAR pre- and post-injection with glucose.(M) Frequency of *Mtb*-specific, TB10.4-TET^+^ cells in lungs and spleen after MET.(N) Cytokine production in TB10.4-TET^+^ cells after re-stimulation with PMA/ionomycin.(O) Polyfunctionality on the basis of co-expression of IFNγ, TNF-α, and IL-2 (single, double, or triple combinations) of TB10.4-TET^+^ cells in (N).A&R, antimycin A and rotenone; F, carbonyl cyanide-4-\[trifluoromethoxy\] phenylhydrazone or FCCP; O, oligomycin. ^∗^ECAR values were normalized to a zero baseline. Statistics, unless otherwise indicated, are relative to UI. Data are representative of two independent experiments (N = 5 mice per group). "p ≤ 0.05, ^\#^p ≤ 0.01, ^∞^p ≤ 0.005, and ^∗^p ≤ 0.001 by one-way ANOVA or unpaired Student's t test. Error bars are mean ± SD.

Similar to previous studies ([@bib51]), we did not observe differences in bacillary burden or histopathology at D21 or D35 post-infection with MET treatment alone ([Figures 6](#fig6){ref-type="fig"}B and 6C). On D21, CD8^+^ T cells from MET-treated, *Mtb*-infected mice displayed very few bioenergetic differences relative to their untreated, infected counterparts ([Figures 6](#fig6){ref-type="fig"}D--6G), although UI+MET cells did have higher MRC and SRC relative to untreated, UI cells ([Figure 6](#fig6){ref-type="fig"}F). However, by D35, relative to untreated, infected mice, CD8^+^ T cells from MET-treated, *Mtb*-infected mice displayed higher basal OCR ([Figure 6](#fig6){ref-type="fig"}H) and an increased capacity to withstand mitochondrial stress ([Figure 6](#fig6){ref-type="fig"}I), evidenced by enhanced MRC and SRC ([Figure 6](#fig6){ref-type="fig"}J). The improved bioenergetics were best illustrated in the energy phenogram, whereby cells from *Mtb*-infected mice clearly shift from quiescent to energetic energy phenotypes after MET treatment ([Figure 6](#fig6){ref-type="fig"}K). Next, we identified whether MET influenced the cells' ability to use glucose as fuel. Glycolysis was reduced by MET treatment (ΔECAR) in *Mtb*-infected mice at D21 and D35 post-infection ([Figure 6](#fig6){ref-type="fig"}L), suggesting that T cells from MET-treated mice are less dependent on glycolysis for energy production, likely because of the restoration of OXPHOS.

Flow cytometry on CD8^+^ T cells from the lungs and spleen revealed a 2-fold increase in the *Mtb*-specific TB10.4-TET^+^ population following MET treatment ([Figure 6](#fig6){ref-type="fig"}M). Interestingly, these *Mtb*-specific cells produced fewer cytokines than their untreated counterparts, evidenced by decreased IL-2 at D21, IFN-γ at D35, and TNF-α at both time points ([Figure 6](#fig6){ref-type="fig"}N). MET treatment also decreased the frequency of polyfunctional T cells at D35 ([Figure 6](#fig6){ref-type="fig"}O).

In sum, these data highlight MET's ability to alter *Mtb*-specific CD8^+^ T cell responses *in vivo*. MET enhanced the number of TB10.4-TET^+^ cells at local and systemic sites during infection, decreased inflammatory cytokine production, most notably TNF-α, and improved mitochondrial bioenergetics in these cells at D35 post-infection. As anticipated, these MET-mediated effects were not unique to infection, as shifts were also observed in UI mice treated with MET, although the effects were smaller in magnitude. These data suggest that MET can reverse the quiescent metabolic state observed in CD8^+^ T cells during chronic *Mtb* infection, rejuvenate OXPHOS, and ultimately enhance the effectiveness of *Mtb*-specific CD8^+^ T cell responses.

Discussion {#sec3}
==========

Metabolism has been largely overlooked as a key driver of the suboptimal immune responses generated during chronic *Mtb* infection. In the present study, we examined the immunometabolic signatures of CD8^+^ T cells from the lungs of mice infected with *Mtb* or the non-pathogenic vaccine strain, BCG, and provide insight into how metabolism may play an important role in the development of protective versus pathogenic immunity. We show that *Mtb* infection corresponds with the metabolic and functional deterioration of CD8^+^ T cells over time, evidenced by the presence of an *Mtb*-specific T cell population displaying significant bioenergetic insufficiencies, declining mitochondrial health, and limited cytokine production, all early indicators of T cell exhaustion. Bioenergetic analyses revealed a progressive decline in mitochondrial respiration as *Mtb* infection progressed that decreased the cells' ability to cope under stress, eventually forcing the cell into a state of metabolic quiescence. This resulted in an increased dependency on residual glycolysis that could be confirmed by carbon tracer studies. Impairment of OXPHOS was also observed in CD8^+^ T cells from *Mtb*-infected mice in response to external activation signals. Furthermore, this reduction in OXPHOS correlated with an increase in markers associated with dysfunctional mitochondria, particularly in TB10.4-TET^+^ cells. Cells that had the highest proportion of dysfunctional mitochondria expressed CTLA-4 alone or in conjunction with PD-1, suggesting that specific immune checkpoint regulators may play important roles in driving this phenotype. Intriguingly, the deterioration of mitochondrial metabolism and elevated markers of mitochondrial dysfunction were not observed in BCG infection. Cytokine production also declined over time in TB10.4-TET^+^ cells, evidenced by a decrease in the quantity and quality of cytokine-producing cells detected at W12. Notably, metabolic intervention was able to modulate the metabolic and functional capacities of CD8^+^ T cells from *Mtb*-infected mice. In summary, we have identified an immunometabolic signature unique to *Mtb* infection that could be exploited by pharmacologic agents that target key energy pathways to improve immunological control of *Mtb*.

Incorrect metabolic remodeling contributes to the breakdown of protective immunity in numerous disease states, including chronic viral infections and cancer ([@bib3], [@bib23], [@bib49], [@bib52]). Many similarities exist between what we have observed during chronic *Mtb* infection and what has been described in early exhausted T cells isolated from mice during chronic LCMV infection ([@bib3]). However, we did not detect increased FAO in the CD8^+^ T cell population during chronic *Mtb* infection; instead, these cells had an increased dependency on glycolysis that was observed only upon glucose deprivation and not under basal conditions. Exhausted HBV-specific CD8^+^ T cells from virus-infected individuals display similar increases in glycolysis, which is thought to compensate for the decrease in mitochondrial function observed ([@bib49]). During *Mtb* infection, we observed the largest shift in glycolysis at D35 post-infection, which also corresponded with the highest levels of IFN-γ and TNF-α production. When metabolic inhibitors were used to alter glycolytic reprogramming (2-DG, etomoxir), we observed greater shifts in cytokine production in CD8^+^ T cells from *Mtb*-infected mice compared with UI and BCG groups. These data suggest that *Mtb* infection conditions T cells to rely more on glycolysis for energy production than cells from UI or BCG-infected mice. Glycolytic reprogramming is part of normal T cell activation, but we would expect these cells to have elevated basal ECAR and display a glycolytic energy phenotype compared with UI cells. Instead, it appears that these cells are relying on glycolysis to compensate for increasing mitochondrial dysfunction, particularly at later stages of infection. The T cell activation assay supported the latter conclusion, evidenced by the fact that T cells from *Mtb*-infected mice were unable to ramp up OXPHOS in response to activation signals. Together, these data shed light on the bioenergetic impairments acquired by CD8^+^ T cells during chronic *Mtb* infection. It will be important to investigate whether similar bioenergetic impairments exist in CD4^+^ T cells, especially because there are important interactions between these two T cell subsets in TB lesions, however, this will be the focus of a future study. With the knowledge that metabolic dysfunction can affect the differentiation, function, and fitness of a cell long term, selectively targeting OXPHOS or glycolysis in these cells could represent an opportunity to improve control of *Mtb* by boosting *Mtb*-specific T cell responses, an approach that is already being explored in cancer ([@bib54]).

Although glycolysis is necessary for T cell activation and the generation of effector proteins ([@bib38]), it is not always beneficial to the cell. Persistent antigen stimulation during chronic infection perpetuates inflammatory signals and increases the energy demands on a cell, promoting dysfunctional states like exhaustion. T cell activation and effector-related signaling pathways were significantly upregulated in CD8^+^ T cells during *Mtb* infection compared with BCG at D21, accompanied by genes associated with apoptosis and exhaustion at W12, suggesting that *Mtb* infection supports an inflammatory state that cannot be sustained long term. Consistent with these findings, we observed an increased proportion of CD8^+^ effector T cells expressing PD-1 and CTLA-4, and the terminal differentiation marker KLRG-1, during *Mtb* infection. KLRG-1 was expressed on ∼80% of TB10.4-TET^+^ cells by W12. Elevated levels of KLRG-1 may be responsible for the lack of CD8^+^ memory precursors generated during *Mtb* infection. Memory T cells rely heavily on mitochondria-derived ATP ([@bib56], [@bib57]); the reverse was observed in CD8^+^ T cells during *Mtb* infection. This suggests that there is insufficient bioenergetic capacity to support memory development, although we did not look specifically at memory markers in this study. Interestingly, AMPK, an important upstream signaling molecule of mTOR, is a metabolic switch that plays a key role in CD8^+^ T cell memory development during infection ([@bib47]) and cancer ([@bib14]). AMPK is one of the mechanistic targets of MET, which has been successful at reversing the phenotype of exhausted TILs in cancer immunotherapy ([@bib14]) and could have similar therapeutic implications in TB.

Targeting metabolic pathways that regulate effector T cell responses can reinvigorate immunity. The anti-diabetic drug MET has been identified as a potential anti-cancer agent and, most recently, a candidate host-directed therapy for TB ([@bib40], [@bib51], [@bib67]). Although we did not observe a reduction in *Mtb* CFUs or pathology with MET treatment, we saw remarkable improvements in CD8^+^ T cell bioenergetics at D35 post-infection that corresponded with a decreased inflammatory profile. Reduced TNF-α production was particularly relevant because TNF-α has been strongly linked to granuloma formation ([@bib37]); similarly, monofunctional, TNF-α-secreting T cells were the strongest predictor of active TB disease in human patients ([@bib22]). MET has previously been shown to decrease inflammatory gene expression in the lungs of *Mtb*-infected mice ([@bib51]), further validating our findings. We postulate that improved CD8^+^ T cell immunometabolism may not have coincided with an immediate effect on bacterial growth because *Mtb* is a slow-growing pathogen (24 h doubling time), and pathology takes time to develop (and recede) in this model; therefore, MET may have a more measurable impact long term. Because the effects of chronic inflammation and metabolic remodeling were most pronounced at W12 in our initial studies, MET could reduce immunopathology and CFUs in the lung at later time points (e.g., W12 post-infection). Investigating the long-term effects of MET on *Mtb* infection remains the focus of a separate study. It is also possible that MET enhanced innate immune control of *Mtb* (e.g., phagocytosis, autophagy, phagolysosome function, antigen presentation), thus indirectly altering CD8^+^ T cell immunometabolism. It will be important to investigate the timing of MET administration, as well as the interactions between immune cell populations over the course of treatment to gain a more in-depth understanding of the mechanisms involved and the clinical implications.

The data presented here represent a significant advancement in the TB field because the results highlight important associations between metabolism and the breakdown of *Mtb* immunity. However, we recognize that further studies are required to delineate whether these observations are the cause or consequence of *Mtb* persistence. Similar to other studies in this interdisciplinary field ([@bib3], [@bib49]), we analyzed the immunometabolic effects of two clinically distinct infections (*Mtb* versus BCG). Given the study design, it is difficult to pinpoint whether the observed differences are due to different infection kinetics (i.e., pathogen burden, immunopathology) or other virulence mechanisms specific to the pathogen; it is likely a combination thereof. Titrating the infectious dose of BCG so that equivalent numbers of *Mtb* and BCG can be compared at each experimental time point, as demonstrated by [@bib20], may control for some of these variables and should be the focus of a future study. Furthermore, without investigating the interaction between innate immune cells and T cells, it is difficult to establish whether dysregulated T cell immunometabolism is a direct or indirect effect of *Mtb* pathogenesis (i.e., mechanisms aimed at subverting innate immunity could have downstream effects on T cell immunity). Previously, we have shown that *Mtb* decelerates macrophage energy metabolism to support its survival *in vitro* ([@bib11]), suggesting that innate and adaptive immunometabolism in TB are linked. Although more mechanistic studies are required to address these questions, these data introduce methodologies and workflows that could be used to improve TB drug discovery and evaluate vaccine efficacy in experimental animal models.

Metabolism represents a key node of regulation in T cell function that can be manipulated by microbial pathogens to enhance or temper immunity. Our findings suggest that the metabolic deceleration of host CD8^+^ T cells may be an underlying mechanism of *Mtb* pathogenesis that leads to the loss of control and eventual breakdown of protective immunity observed in chronic *Mtb* infection. Furthermore, we demonstrate how metabolic intervention can improve the metabolic flexibility of these cells and fine-tune effector responses, although these effects require more in-depth study to determine whether they improve *Mtb* control long term. Developing metabolically targeted immunotherapies for TB could boost productive effector T cell responses at the site of infection and improve the fitness of circulating memory T cell populations; they could be used in combination with existing anti-TB treatment or developed to vastly improve the outcome of multidrug-resistant TB. Ultimately, by understanding how metabolism and immunity are linked in TB disease, it may be possible to identify, target, and reverse key immunometabolic checkpoints in T cell-mediated immunity to promote *Mtb* clearance and bolster resistance to reinfection.

STAR★Methods {#sec5}
============

Key Resources Table {#sec5.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-CD16/CD32BiolegendCat\# 101302Anti-CD3/CD28 DynabeadsLife TechnologiesCat\# 114.53Danti-CD45 (30-F11) AF700 Rat Anti-MouseBD BiosciencesCat\# 560510anti-CD3 (17A2) PE-Cy7 Rat Anti-Mouse CD3 Molecular ComplexBD BiosciencesCat\# 560591anti-CD4 (RM4-5) BV605 Rat Anti-MouseBD BiosciencesCat\# 563151anti-CD8a (53-6.7) V500BD BiosciencesCat\# 560776anti-IFNγ (XMG1.2) BV786BD BiosciencesCat\# 563773anti-CD44 (IM7) BV650BiolegendCat\# 103049anti-PD-1 (29F.1.A12) PE Anti-Mouse CD279BiolegendCat\# 135205anti-KLRG-1 (2F1/KLRG1) APCBiolegendCat\# 138411anti-CTLA4 (UC10-4B9) PerCP/Cy5.5BiolegendCat\# 106315anti-TNFα (MP6-XT22) BV11 Anti-mouseBiolegendCat\# 506349anti-IL-10 (JES5-16E3) PerCP/ Cy5.5BiolegendCat\# 505028anti-IL-2 (JES6-5H4) FITCBiolegendCat\# 503805anti-IL-2 (JES6-5H4) PE-Dazzle 594BiolegendCat\# 503840**Bacterial and Virus Strains***Mycobacterium tuberculosis* (*Mtb*) strain H37RvATCCCat\# 27294*Mycobacterium bovis,* Danish BCG vaccine strain 1331 (BCG)Stratens Serum InstitutN/A**Chemicals, Peptides, and Recombinant Proteins**Metformin hydrochloride (Glucophage 500mg film-coated tablets)MerckReg No: 41/21.2/0639Middlebrook 7H11 AgarBD BiosciencesCat\# 283810Middlebrook OADCBD BiosciencesCat\# 212240Middlebrook 7H9 BrothBD BiosciencesCat\# 271310Collagenase DRocheCat\# 11088866001DNaseRocheCat\# 10104159001ACK Lysis BufferLonzaCat\# 10-548ECell-takCorningCat\# 354241RPMI1640LonzaCat\# BE12-167FGlutaMaxGIBCOCat\# 35050-038Oligomycin (from Streptomyces diastatochromogenes)SigmaCat\# O4876carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP)SigmaCat\# C2920Antimycin ASigmaCat\# A8674RotenoneSigmaCat\# R8875Phorbol 12-myristate 13-acetateSigmaCat\# P8139Ionomycin Calcium SaltSigmaCat\# 10634Brefeldin ASigmaCat\# B7651K^b^ TB10.4-TET~4-11~ (IMYNPAM) MHC class I tetramerNIH Tetramer Core FacilityN/A**Critical Commercial Assays**RNeasy Micro kitQIAGENCat\# 74004iMAG CD8 T Lymphocyte Enrichment kitBDCat\# 558471Foxp3 Intracellular Staining KiteBioscienceCat\# 00-5523-00LIVE/DEAD Fixable Dead Cell Stain 633/635nm excitationLife TechnologiesCat\# L10119MitoTracker Green (MTG)Life TechnologiesCat\# M7514Mitotracker Deep Red (MTDR)Life TechnologiesCat\# M22426MitoSox RedLife TechnologiesCat\# M360082-\[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino\]-2-deoxy-D-glucose (2-NBDG)Life TechnologiesCat\# N13195Seahorse XF Cell Mito Stress Test KitAgilent TechnologiesCat\# 103015-100Seahorse XF Glycolysis Stress Test KitAgilent TechnologiesCat\# 103020-100**Deposited Data**Raw and analyzed dataThis paperGEO: [GSE117330](ncbi-geo:GSE117330){#intref0010}Mouse reference genome Gencode Release M11, GRCm38 p4Gencode<https://www.gencodegenes.org/>**Experimental Models: Organisms/Strains**Mouse: C57BL/6JBred in-house (AHRI)N/A**Software and Algorithms**Wave desktop software, Version 2.6Agilent<https://www.agilent.com/en/products/cell-analysis/cell-analysis-software/data-analysis/wave-desktop-2-6>Bcl2fastq version 2.18.0.12Illumina<https://www.illumina.com/index-d.html>STAR version 2.5.3a[@bib12]<https://github.com/alexdobin/STAR>HTSeq-count version 0.9.1[@bib1]<https://htseq.readthedocs.io/en/release_0.11.1/index.html#>DESeq2 version 1.24.0[@bib36]<https://bioconductor.org/packages/release/bioc/html/DESeq2.html>Ingenuity Pathway AnalysisQIAGEN<https://www.qiagenbioinformatics.com/>Skyline V3.7[@bib39]<https://skyline.ms/project/home/software/Skyline/begin.view>Analyst software package, Version 1.6.2AB/MDS Sciex<https://sciex.com/products/software/analyst-software>

Lead Contact and Materials Availability {#sec5.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Adrie JC Steyn (<asteyn@uab.edu>). This study did not generate unique reagents.

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

### Mice {#sec5.3.1}

Six- to eight-week old female C57BL/6J mice (bred in-house at the Africa Health Research Institute) were used for all *in vivo* experiments. Littermates were randomly assigned to experimental groups. All mice were housed 5 mice per cage and were given environmental enrichment. Food and water was provided *ad libitum*. All procedures were approved by the Animal Ethics Sub-Committee at the University of KwaZulu-Natal (reference number AREC/003/016PD). Mice were cared for in accordance with South African national guidelines.

### Bacteria {#sec5.3.2}

*Mycobacterium tuberculosis (Mtb)*, strain H37Rv (ATCC 27294) and *Mycobacterium bovis* BCG (Danish 1331 strain, Statens Serum Institut) were cultured in 7H9 medium (BD) supplemented with 10% OADC (BD). Bacteria were cultured to an O.D. of 1.0 and diluted 1/100 in 7H9/OADC medium prior to aerosol infection.

Method Details {#sec5.4}
--------------

### Study design {#sec5.4.1}

According to a study by [@bib19] only a small fraction (8%) of T cells in TB granulomas produce cytokines when re-stimulated with extracts from *Mtb*-infected lungs, *Mtb*-specific peptides or *Mtb*-infected dendritic cells, suggesting that many T cells recruited to these lesions cannot produce cytokines because (1) cytokine production is inhibited, or (2) the majority of T cells recruited are not specific for mycobacterial antigens. Based on this work and others, in this study we chose to view the *Mtb*-infected lung holistically. In most instances, we compare the immunometabolic signatures represented by the total CD8^+^ T cell populations from uninfected, BCG and *Mtb*-infected mice. We believe there is strong justification for this approach because of the complex, multicellular architecture of TB lesions, especially considering the broad effects imposed on these cells during chemotherapy. To provide additional context, we compare these readouts with a subset of *Mtb*-specific CD8^+^ T cells (TB10.4~4-11~-specific), acknowledging that the immunometabolic characteristics we observe may not be generalizable to all *Mtb*-specific CD8^+^ T cells. We anticipate this study design will provide the basis for further research, particularly as it pertains to developing innovative approaches to test candidate host-directed therapies or assess vaccine efficacy.

We chose to include BCG in this study because of its relevance as the most widely used vaccine strain globally, its extensive use in laboratory research settings, and its mild clinical presentation, for comparative purposes with virulent *Mtb*.

### Bacterial infections and drug treatment {#sec5.4.2}

Six- to eight-week old C57BL/6J mice (bred in-house) were aerosol-infected with ∼100 CFU of virulent *M. tuberculosis*, strain H37Rv (ATCC 27294) or *M. bovis* BCG (Danish 1331, Statens Serum Institut) using a Glas-Col Aerosol Exposure System. Mice were euthanized on day 21, day 35 and 12 weeks post-infection by cervical dislocation under anesthesia (isoflurane), and lungs and spleen were aseptically removed. For the drug experiments, 7 days post-infection, mice were treated with metformin hydrochloride by oral gavage (500 mg/kg/day) 5 days per week for 4 weeks.

### Bacterial enumeration and T cell isolation {#sec5.4.3}

Individual mouse lungs were homogenized in 10 mL sterile PBS/0.02% Tween 80 using a gentleMACS Dissociator (Miltenyi). Bacteria were enumerated by plating 10-fold serial dilutions onto 7H11 agar (BD) supplemented with 10% OADC (BD) and PACT (Sigma). Colonies were counted 3-4 weeks later. For functional assays, lungs were perfused with PBS to eliminate contaminating blood cells, homogenized in 5 mL 0.5mg/mL Collagenase D with 20 μg/mL DNase (Roche), incubated for 30 min at 37°C, then passed through a 70 μM cell strainer (BD). Red blood cells were lysed with ACK lysis buffer (GIBCO) and remaining cells were prepared for downstream analyses. CD8^+^ T cells were purified from white blood cell suspensions by negative magnetic bead selection using the Mouse CD8 T Lymphocyte Enrichment kit (iMAG, BD).

### RNA preparation, sequencing, and analysis {#sec5.4.4}

RNA was extracted from 1.2 × 10^6^ CD8^+^ T cells from UI and infected (BCG or *Mtb*) mouse lungs using the RNeasy Micro kit (QIAGEN). RN/RQ values were measured using the Agilent 2100 Bioanalyzer. Samples for RNASeq were isolated from 5 mice per group. Three of the highest quality samples (based on RN/RQ values) were submitted for sequencing at the University of Alabama Heflin Genomics Core Facility.

mRNA sequencing was performed on the Illumina NextSeq500 as described by the manufacturer (Illumina). Library preparation was performed using the SureSelect Strand Specific mRNA library kit as per the manufacturer's instructions (Agilent). Library construction began with two rounds of polyA selection using oligo dT-containing magnetic beads. The resulting mRNA was randomly fragmented with cations and heat, followed by first strand synthesis using random primers with inclusion of Actinomycin D (2.4ng/μL). Second strand cDNA production was performed using standard techniques and the ends of the resulting cDNA were blunted, A-tailed and adaptors ligated for indexing to allow for multiplexing during sequencing. cDNA libraries were quantitated using qPCR (Roche, LightCycler 480) with the Kapa Biosystems kit for Illumina library quantitation (Kapa Biosystems) prior to cluster generation. Cluster generation was performed according to manufacturer's recommendations for onboard clustering (Illumina). Paired-end 75bp sequencing runs were used to allow for better alignment to the reference genome.

STAR (version 2.5.3a) was used to align the raw RNA-Seq fastq reads to the mouse reference genome (GRCm38 p4, Release M11) from Gencode ([@bib12]). Following alignment, HTSeq-count (version 0.9.1) was used to count the number of reads mapped to each gene ([@bib1]). Normalization and differential expression was then applied to the count files using DESeq2 ([@bib36]). Genes considered significant Genes considered significant had a fold-change value ≥ +/−2. Principal component analysis (PCA) plots were generated using the normalized dataset in DESeq2. Heatmap generation was done in R version 3.4.3 using gplots version 3.0.1 heatmap.2 function. In brief, fold change values for each group were loaded into R as a data matrix. The gplots heatmap.2 was then used to plot the data matrix using the arguments: scale = "row," key = T, keysize = 1.5, col = bluered (75), density.info = "none," trace = "none," labRow = F. Raw sequence reads were uploaded to NCBI Gene Expression Omnibus (GSE117330).

### Gene set enrichment analysis {#sec5.4.5}

To generate networks, a dataset containing gene identifiers and corresponding expression values was uploaded into Ingenuity Pathway Analysis (QIAGEN). Each identifier was mapped to its corresponding object in Ingenuity's Knowledge Base. A fold change cutoff of ± 2 and p value \< 0.05 was set to identify molecules whose expression was significantly differentially regulated. These molecules, called Network Eligible molecules, were overlaid onto a global molecular network developed from information contained in Ingenuity's Knowledge Base. Networks of Network Eligible Molecules were then algorithmically generated based on their connectivity. The Functional Analysis identified the biological functions and/or diseases that were most significant to the entire dataset. Molecules from the dataset that met the fold change cutoff of ± 2 and p value \< 0.05, and were associated with biological functions and/or diseases in Ingenuity's Knowledge Base were considered for the analysis. Right-tailed Fisher's exact test was used to calculate a p value determining the probability that each biological function and/or disease assigned to that dataset was due to chance alone.

### Metabolic extracellular flux analysis {#sec5.4.6}

Seahorse extracellular flux (XF) experiments were performed on total CD8^+^ T cells from UI and infected mice purified using negative magnetic bead selection as described above. *Mtb*-specific TB10.4-tetramer^+^ cells were sorted using the FACSAria II (BD Biosciences). Total CD8^+^ T cells were sorted alongside tetramer^+^ cells to serve as sorted controls. CMST parameters were measured in XF media (non-buffered RPMI 1640 medium, containing 25 mM glucose, 2 mM L-glutamine, and 1mM sodium pyruvate). Cells (250,000 live cells/well) were adhered to the plate using Cell-Tak (Corning) as previously described ([@bib31]). Briefly, 10 μL of Cell-Tak reagent (135 mL Cell-Tak, 270 mL dH2O, 810 mL of 0.1 N sodium bicarbonate (pH 8.0), followed by adjusting the pH to 7.2--7.8 with 1 N NaOH) was added to each well of the XF plate, incubated for 30 min at 37°C and then washed off using three rinses with dPBS. Cells were spun down onto the XF plate at 1500 rpm for 5 min with the break off, and the plate with flipped around and the same spin was done with the plate in the opposite orientation to create a uniform monolayer of cells across the bottom of the well. Cells were equilibrated for 1h at 37°C, and assayed for OCR and ECAR under basal conditions, and in response to 1.25 μM oligomycin, 1.5 μM FCCP, 200 μM etomoxir, 25 mM 2-deoxyglucose (2-DG), 100 nM rotenone/1 μM antimycin A (all Sigma). Activation bioenergetics were measured by incubating purified CD8^+^ T cells with anti-CD3/anti-CD28 Dynabeads (Life Technologies) for 1h at 37°C prior to initiating the run. In the glycolysis stress test (GST) assay, cells were equilibrated in glucose-free media for 1h prior to initiating the run and glucose was injected (10 μM) at the beginning of the run to measure the cells' dependency on glycolysis. Cells were assayed on an XF-96 Extracellular Flux Analyzer (Agilent). Measurements were normalized to total μg protein in each well using a Bradford assay (BioRad).

Briefly, in the CMST, injection of oligomycin, an inhibitor of ATP synthase, provides an estimate of mitochondria-derived ATP production, injection of FCCP, a mitochondrial uncoupler, pushes the cell to its maximal respiratory capacity (MRC), and injection of antimycin A and rotenone shuts down the electron transport chain, revealing non-mitochondrial oxygen consumption. The CMST can also quantify a cell's spare respiratory capacity (SRC), which is a measurement of the cell's ability to increase respiration when the energy demand exceeds supply - under conditions of stress or increased workload.

Bioenergetic phenograms were generated by plotting OCR as a function of ECAR after FCCP addition to illustrate how mitochondrial stress impacts the energy phenotype of the cell population in question. The energy phenotype of cells can be described as more aerobic, energetic, glycolytic or quiescent.

### MHC tetramers, antibodies, and flow cytometry {#sec5.4.7}

For mitochondrial assays, purified cells were incubated with 50 nM MitoTracker Green (MTG) and 12.5 nM Mitotracker Deep Red (MTDR) in RPMI 1640 (GIBCO) containing 10% FBS, 2 mM L-glutamine for 30 min at 37°C prior to staining. Mitochondrial superoxides were assessed using 5 μM MitoSox Red incubated for 10 min at 37°C in HBSS. Glucose uptake was assayed by incubating cells with 100 μM 2-\[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino\]-2-deoxy-D-glucose (2-NBDG) at 37°C in glucose-free RPMI 1640 (GIBCO) containing 10% FBS, 2 mM L-glutamine for 30 min prior to FACS staining. MTG, MTDR, MitoSox and 2-NBDG were obtained from Life Technologies.

Intracellular cytokine production in purified cells was assessed by incubating 1x10^6^ cells with 50 ng/mL phorbol 12-myristate 13-acetate (PMA) and 1 μg/mL ionomycin for 4 h. Brefeldin A (10 μg/mL) was added 1 h prior to surface staining. All reagents were obtained from Sigma. With the likelihood that only a small percentage of CD8^+^ T cells produce cytokines in response to *Mtb* antigens ([@bib19]), we chose the non-specific re-stimulation method PMA/ionomycin because it could be broadly applied to all three groups of T cells (UI, *Mtb*-infected, BCG-infected) for comparison purposes.

For flow cytometry analyses, purified cells were blocked with rat anti-mouse CD16/CD32 (Biolegend) and stained with anti-CD45 (30-F11), anti-CD3 (17A2), anti-CD4 (RM4-5), anti-CD8a (53-6.7), anti-IFN-γ (XMG1.2)(BD Biosciences), anti-CD44 (IM7), anti-PD-1 (29F.1.A12) anti-KLRG-1 (2F1/KLRG1), anti-CTLA4 (UC10-4B9) anti-TNFα (MP6-XT22), anti-IL-10 (JES5-16E3, anti-IL-2 (JES6-5H4) (Biolegend). K^b^ TB10.4-TET~4-11~ (IMYNPAM) MHC class I tetramer was obtained from the NIH Tetramer Core Facility (Emory University, Atlanta, GA). Cells were stained with tetramer (1:200) and/or extracellular antibodies at 4°C for 30 min. If required, cells were fixed and permeabilized using the Foxp3 Intracellular Staining Kit (eBioscience). Prior to antibody staining, cells were stained with the LIVE/DEAD Fixable Dead Cell Stain (Life Technologies) to exclude dead cells from the analysis. Flow cytometry was performed using an LSRII Fortessa or FACSAriaII (BD Biosciences) and data were analyzed with FlowJo V10.1 software (TreeStar).

Importantly, all TB10.4-TET^+^ cells described in this study refer to antigen-specific T cells from *Mtb*-infected mice, not BCG; although there is a TB10.4 homolog in BCG, we were unable to detect TB10.4-TET^+^ cells in BCG-infected mice.

### Carbon Tracing, Metabolite Extraction and Mass Spectrometry Analysis {#sec5.4.8}

Carbon tracing experiments were performed on total CD8^+^ T cells purified as described above. 1x10^6^ cells were cultured at 37°C with 5% CO~2~ for 1 h in 1 mL glucose-free RPMI 1640 (GIBCO) containing 10% FBS, 2 mM L-glutamine and 25 mM ^13^C~6~-glucose (Sigma). Metabolites were extracted in 700 μL 50:50 H~2~O:MeOH containing 51.2 mg/mL para-nitrophenyl-phosphate (pNPP) standard (Sigma). Samples were stored at −80°C overnight and spun through a 0.22 μM filter (Corning), dried down and reconstituted in 100 μL ddH~2~O. Metabolites were separated on a Biorad Aminex HPX-87 column (300 × 7.8mm), using an aqueous 0.1% formic acid isocratic mobile phase, connected to a Dionex Ultimate 3000 UPLC. Total negative ion chromatograms (50 -- 750 m/z scan range) were collected using a Thermo Scientific Q Exactive mass spectrometer. The total ion chromatograms of all relevant metabolites, and their respective isotopologues, were visualized and analyzed using Skyline V3.7 ([@bib39]).

AXP levels were quantified using methods described previously with minor modifications ([@bib32]). Metabolite extracts were prepared from CD8^+^ T cells as described above, purified in RPMI 1640 media containing unlabeled glucose. Extracts were run on the Agilent 1200 series binary HPLC system (Agilent) coupled to an Applied Biosystems/MDS Sciex QTRAPTM 5500 linear accelerator trap mass spectrometer (AB/MDS Sciex) fitted with an ESI source. The mass spectrometer was operated in negative ion mode and samples were analyzed using multi reaction monitoring (MRM). Data were acquired and analyzed using the Analyst (Version 1.6.2) software package (AB/MDS Sciex). The ATP/ADP/AMP precursor ion/product ions monitored were the following respectively: 505.9 m/z with 159 m/z and 78.8 m/z, 425.9 with 133.9 m/z and 78.9 m/z, and 345.9 m/z with 96.8 m/z and 78.9 m/z. AXP levels were quantified using a method of standard addition and normalized to total ug protein as measured by Bradford assay (BioRad).

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

Differences between control and experimental groups were compared using a one-way analysis of variance (ANOVA) with multiple comparisons to calculate statistical significance (GraphPad Prism software, version 7.0). In instances where only two groups were compared, an unpaired Student's t test was used (GraphPad Prism). All animal experiments were performed with five mice per experimental group, unless additional mice were required (up to 10 mice/group) for experiments requiring larger cell numbers or for the analysis of cell populations present in lower frequencies (e.g., TB10.4-TET^+^ cells). Samples were pooled for subsequent XF96 (CMST and GST), metabolomic, intracellular, and extracellular flow cytometry and mitochondrial fitness analyses to ensure all experimental tests could be performed in parallel in a single animal experiment, under BSL3 conditions. No pooling was done for CFU experiments or transcriptomic analyses. Further information with regard to specific experiments, including the number of experimental replicates, can be found in the figure legends.

Data and Code Availability {#sec5.6}
--------------------------

The accession number for the raw RNA-sequencing data reported in this paper is GEO accession number GEO:([GSE117330](ncbi-geo:GSE117330){#intref0065}). All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials except for the transcriptomic data. Raw sequence reads were uploaded to NCBI Gene Expression Omnibus ([GSE117330](ncbi-geo:GSE117330){#intref0070}). Additional data related to this paper may be requested from the authors.
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